The abstract is read at the publisher; the summary is JClub's.
[225Ac]Ac-Macropa-M16AB achieved complete remissions in MUC-16-positive ovarian and pancreatic ductal adenocarcinoma patient-derived xenografts, with 100% sustained CRs in high/medium expressers.
- Why it matters: MUC-16 is frequently overexpressed in epithelial ovarian cancer and pancreatic ductal adenocarcinoma, but effective targeted radiotherapy requires demonstrating tumor control linked to antigen expression.
- What they did: The radioimmunoconjugate was characterized in vitro, then evaluated for pharmacokinetics, biodistribution, hematologic safety, and dosimetry in healthy mice; efficacy used two doses (13 or 18.6 kBq) given 10 days apart in SW1990 CDX and MUC-16–varying EOC/PDAC PDXs.
- The result: In SW1990 CDX, 16.7% of mice reached complete remission while 83.3% had durable suppression for ≥50 days; in high/medium MUC-16 PDXs, 100% sustained CRs occurred, and low MUC-16 EOC showed growth inhibition and prolonged survival.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.